Interleukin-6 is present in early stages of plaque formation and is restricted to the brains of Alzheimer's disease patients
The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Interleukin-6 (IL-6) immunoreactivity has previously been shown in plaques in Alzheimer's disease (AD) and elevated IL-6 concentrations have been measured biochemically in brains of AD patients. In this study, we investigated the appearance of IL-6 immunoreactivity in AD plaques according to the stage of plaque formation. Using the Bielschowsky silver-staining method, we were able to differentiate between four types of plaques described earlier: diffuse, primitive, classic and compact. While diffuse plaques represent the early stage of plaque formation, primitive and classic plaques are thought to represent later stages of plaque development. We investigated serial sections of paraffin-embedded cortices of ten clinically diagnosed and histopathologically confirmed AD patients and ten patients with no clinical history of dementia. We found plaques in the brains of both nondemented and demented persons using the silver staining method or immunohistochemistry with antibodies against the amyloid precursor protein. In the group of clinically nondemented persons, diffuse plaques were the predominant plaque type, whereas primitive plaques formed the larger portion of lesions in the group of AD brains. IL-6 could not be detected in plaques of patients without dementia. Many IL-6-positive plaques were found in six of the AD brains and to a smaller extent in the other four AD cases. In the six cases with a large number of IL-6-positive plaques, IL-6 was found in a significantly higher…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interleukin-6, a typical SASP mediator, is upregulated in the aged brain and in AD [96,97,98] and its overexpression has been shown to drive neurodegeneration in vivo [99].”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [97]
In the citing paper
“Most notably, IL-6, IL-1β, TGF-β and TNF-α levels have been reported to be elevated in AD brain tissue [96,97,212,213,214]”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [97]
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Terry, R. D., Masliah, E., Salmon, D. P., Butters, N., DeTeresa, R., Hill, R., Hansen, L. A., & Katzman, R. (1991) · Annals of Neurology · doi:10.1002/ana.410300410 · Cited by 4,397
Baumann, H., & Gauldie, J. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90137-6 · Cited by 2,899
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6.
Campbell, I. L., Abraham, C. R., Masliah, E., Kemper, P., Inglis, J. D., Oldstone, M. B., & Mucke, L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.10061 · Cited by 1,006
Abraham, C. R., Selkoe, D. J., & Potter, H. (1988) · Cell · doi:10.1016/0092-8674(88)90462-x · Cited by 900
Roberts, G. W., Gentleman, S. M., Lynch, A., Murray, L., Landon, M., & Graham, D. I. (1994) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.57.4.419 · Cited by 569
Excitatory amino acids and Alzheimer's disease
Greenamyre, J. T., & Young, A. B. (1989) · Neurobiology of Aging · doi:10.1016/0197-4580(89)90143-7 · Cited by 484
Research works printed but not linked: 4
- Ikeda S, Glenner GG (1989) Morphology and distribution of plaque and related deposits in the brains of Alzheimer's disease and control cases. Lab Invest 60:113?122
- Jellinger K, Bancher C, Fischer P, Lassmann H (1992) Quantitative histopathologic validation of senile dementia of the Alzheimer type. Eur J Gerontol 3:146?156
- Mirra SS, Hart MN, Terry RD (1993) Making the diagnosis of Alzheimer's disease. Arch Pathol Lab Med 117:132?144
- Wisniewski HM, Terry RD (1973) Reexamination of the pathogenesis of the senile plaque. Prog Neuropathol 2:1?26
Cited by
Inflammation as a central mechanism in Alzheimer's disease
Kinney, J. W., Bemiller, S. M., Murtishaw, A. S., Leisgang, A. M., Salazar, A. M., & Lamb, B. T. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.06.014 · Cited by 2,253
Age-Associated Increased Interleukin-6 Gene Expression, Late-Life Diseases, and Frailty
Ershler, W. B., & Keller, E. T. (2000) · Annual Review of Medicine · doi:10.1146/annurev.med.51.1.245 · Cited by 1,282
Kitazawa, M., Oddo, S., Yamasaki, T. R., Green, K. N., & LaFerla, F. M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2868-05.2005 · Cited by 697
“Because activated microglia secrete various cytokines, we monitored the expression of selected cytokines, including IL1 , IL-6, and TNF , which have been suggested to play important roles in the progression of AD (Griffin et al., 1989; Dickson et al., 1993; Huell et al., 1995).”
BackgroundResultPoynter, M. E., & Daynes, R. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32833 · Cited by 550
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448
Kynurenines in CNS disease: regulation by inflammatory cytokines.
Campbell, B. M., Charych, E., Lee, A. W., & Möller, T. (2014) · Frontiers in Neuroscience · doi:10.3389/fnins.2014.00012 · Cited by 409
“Similar changes are found in post-mortem brain tissue along with IL-6 also increased (Huell et al., 1995).”
ResultPhysiological and pathological roles of interleukin-6 in the central nervous system
Gruol, D. L., & Nelson, T. E. (1997) · Molecular Neurobiology · doi:10.1007/bf02740665 · Cited by 404
“For example, IL-6 immunoreactivity is found in amyloid plaques in the CNS of patients with Alzheimer's disease but not in plaques in the CNS from control patients without dementia (Kossmann et al., 1995; Bauer et al., Strauss et al., 1992; Hull et al., 1996; Huell et al., 1995).”
BackgroundLicastro, F., Pedrini, S., Caputo, L., Annoni, G., Davis, L. J., Ferri, C., Casadei, V., & Grimaldi, L. M. E. (2000) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00226-x · Cited by 400
Interleukin-6, a mental cytokine
Spooren, A., Kolmus, K., Laureys, G., Clinckers, R., De Keyser, J., Haegeman, G., & Gerlo, S. (2011) · Brain Research Reviews · doi:10.1016/j.brainresrev.2011.01.002 · Cited by 352
“neuropathological changes (Huell et al., 1995), indicating it is probably not a mere consequence of neurodegeneration.”
BackgroundLyra e Silva, N. M., Gonçalves, R. A., Pascoal, T. A., Lima-Filho, R. A. S., Resende, E. D. P. F., Vieira, E. L. M., Teixeira, A. L., de Souza, L. C., Peny, J. A., Fortuna, J. T. S., et al. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01349-z · Cited by 347
Chakrabarty, P., Jansen‐West, K., Beccard, A., Ceballos‐Diaz, C., Levites, Y., Verbeeck, C., Zubair, A. C., Dickson, D., Golde, T. E., & Das, P. (2010) · The FASEB Journal · doi:10.1096/fj.09-141754 · Cited by 328
“The proinflammatory cytokine IL-6 has been proposed to play a potentiating role in AD based on increased IL-6 levels in the brains, cerebrospinal fluid, and plasma of AD patients and the proximity of IL-6 reactivity around A plaques (2, 15, 28, 29).”
BackgroundCytokine dysregulation in autism spectrum disorders (ASD): Possible role of the environment
Goines, P. E., & Ashwood, P. (2013) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2012.07.006 · Cited by 314
Apelt, J., & Schliebs, R. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03176-0 · Cited by 257
Cellular Senescence in Neurodegenerative Diseases
Martínez-Cué, C., & Rueda, N. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00016 · Cited by 281
Inhibition of NF-κB potentiates amyloid β-mediated neuronal apoptosis
Kaltschmidt, B., Uherek, M., Wellmann, H., Volk, B., & Kaltschmidt, C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9409 · Cited by 279
Self-citationAdvanced glycation endproducts in ageing and Alzheimer's disease
Münch, G., Thome, J., Foley, P., Schinzel, R., & Riederer, P. (1997) · Brain Research Reviews · doi:10.1016/s0165-0173(96)00016-1 · Cited by 275
Sokolova, A., Hill, M. D., Rahimi, F., Warden, L. A., Halliday, G. M., & Shepherd, C. E. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00188.x · Cited by 249
“The identification of interleukin-1b (IL-1b) (17), interleukin-6 (IL-6) (3, 20), tumor necrosis factor-a (TNF-a, (8), monocyte chemoattractant protein-1 (MCP-1) (22) and macrophage inflammatory protein-1b (50) in senile plaques and/or associated microglia has further highlighted the importance of inflammation in AD.”
BackgroundResultIL-6 regulation of synaptic function in the CNS
Gruol, D. L. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.023 · Cited by 254
“…disease, a disease characterized by dementia, memory loss and other cognitive problems (Bermejo et al., 2008; Cojocaru et al., 2011; Hampel et al., 2005; Huell et al., 1995; Luterman et al., 2000; Strauss et al., 1992; Swardfager et al., 2010; Trapero and Cauli, 2014; Wood et al., 1993).”
Cyclooxygenase expression in microglia and neurons in Alzheimer's disease and control brain
Hoozemans, J. J. M., Rozemuller, A. J. M., Janssen, I., De Groot, C. J. A., Veerhuis, R., & Eikelenboom, P. (2001) · Acta Neuropathologica · doi:10.1007/s004010000251 · Cited by 246
Ilschner, S., & Brandt, R. (1996) · Glia · doi:10.1002/(sici)1098-1136(199610)18:2<129::aid-glia5>3.0.co;2-w · Cited by 46
Self-citationPeripheral inflammatory biomarkers in Alzheimer’s disease: a brief review
Park, J.-C., Han, S.-H., & Mook-Jung, I. (2020) · BMB Reports · doi:10.5483/bmbrep.2020.53.1.309 · Cited by 201
Mehlhorn, G., Hollborn, M., & Schliebs, R. (2000) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(00)00012-5 · Cited by 198
Dominici, R., Cattaneo, M., Malferrari, G., Archi, D., Mariani, C., Grimaldi, L., & Biunno, I. (2002) · Immunogenetics · doi:10.1007/s00251-002-0445-9 · Cited by 192
Constitutive activation of NF-kappa B in an animal model of aging
Spencer, N. (1997) · International Immunology · doi:10.1093/intimm/9.10.1581 · Cited by 187
Neuroinflammatory perspectives on the two faces of Alzheimer?s disease
Eikelenboom, P., & van Gool, W. A. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-003-0055-1 · Cited by 182
“Activated microglial cells, particularly those in the vicinity of neuritic plaques have shown to be immunoreactive for interleukin-1 (Il-1), interleukin-6 (Il-6), and tumour necrosis factor-a (TNF-a) (Griffin et al., 1989; Dickson et al., 1993, Huell et al., 1995).”
Licastro, F., Grimaldi, L. M. E., Bonafè, M., Martina, C., Olivieri, F., Cavallone, L., Giovanietti, S., Masliah, E., & Franceschi, C. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(03)00013-7 · Cited by 182
Bermejo, P., Martín-Aragón, S., Benedí, J., Susín, C., Felici, E., Gil, P., Ribera, J. M., & Villar, Á. M. (2008) · Immunology Letters · doi:10.1016/j.imlet.2008.02.002 · Cited by 178
Prostaglandins and other lipid mediators in Alzheimer’s disease
Bazan, N. G., Colangelo, V., & Lukiw, W. J. (2002) · Prostaglandins & Other Lipid Mediators · doi:10.1016/s0090-6980(02)00031-x · Cited by 173
Interleukin-6 in the aging brain
Godbout, J. P., & Johnson, R. W. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.10.031 · Cited by 173
“, 1991) and is also detectable prior to amyloid plaque formation (Huell et al., 1995).”
BackgroundAging and Neurodegenerative Disease: Is the Adaptive Immune System a Friend or Foe?
Mayne, K., White, J. A., McMurran, C. E., Rivera, F. J., & de la Fuente, A. G. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.572090 · Cited by 167
Tha, K. K., Okuma, Y., Miyazaki, H., Murayama, T., Uehara, T., Hatakeyama, R., Hayashi, Y., & Nomura, Y. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02883-3 · Cited by 163
Transforming Growth Factor-β1 Potentiates Amyloid-β Generation in Astrocytes and in Transgenic Mice
Lesné, S., Docagne, F., Gabriel, C., Liot, G., Lahiri, D. K., Buée, L., Plawinski, L., Delacourte, A., MacKenzie, E. T., Buisson, A., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300819200 · Cited by 143
Ringheim, G. E., Szczepanik, A. M., Petko, W. W., Burgher, K. L., Zhu, S. Z., & Chao, C. C. (1998) · Molecular Brain Research · doi:10.1016/s0169-328x(97)00356-2 · Cited by 144
Kim, E., Kim, H., Jedrychowski, M. P., Bakiasi, G., Park, J., Kruskop, J. M., Choi, Y., Kwak, S. S., Quinti, L., Kim, D. Y., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.08.012 · Cited by 149
Neural activities of IL‐6‐type cytokines often depend on soluble cytokine receptors
März, P., Otten, U., & Rose‐John, S. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00755.x · Cited by 126
Reale, M., Iarlori, C., Gambi, F., Feliciani, C., Salone, A., Toma, L., Luca, G. D., Salvatore, M., Conti, P., & Gambi, D. (2004) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.11.003 · Cited by 130
Parthsarathy, V., & Hölscher, C. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.12.012 · Cited by 119
“Interleukin-6 (IL-6) is found in the brains of Alzheimer patients (Huell et al., 1995).”
BackgroundKordula, T., Rydel, R. E., Brigham, E. F., Horn, F., Heinrich, P. C., & Travis, J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.7.4112 · Cited by 119
Essa, M. M., Subash, S., Akbar, M., Al-Adawi, S., & Guillemin, G. J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0120964 · Cited by 117
“formation and expression of this cytokine was correlated with clinical dementia [94].”
BackgroundAre there roles for brain cell senescence in aging and neurodegenerative disorders?
Tan, F. C. C., Hutchison, E. R., Eitan, E., & Mattson, M. P. (2014) · Biogerontology · doi:10.1007/s10522-014-9532-1 · Cited by 116
“It is important to note, however, that p38MAPK also plays a central role in immune activation (Cuenda and Rousseau 2007) that is unre- lated to CS and it is therefore difficult to conclude how much of its observed activity in the CNS is due to CS. Cytokines such as IL-6 that are characteristic of SASP are found elevat…”
InfluentialAstrocytes from old Alzheimer's disease mice are impaired in Aβ uptake and in neuroprotection
Iram, T., Trudler, D., Kain, D., Kanner, S., Galron, R., Vassar, R., Barzilai, A., Blinder, P., Fishelson, Z., & Frenkel, D. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.08.001 · Cited by 115
S100β Induction of the Proinflammatory Cytokine Interleukin‐6 in Neurons
Yuekui, L., Barger, S. W., Liu, L., Mrak, R. E., & Griffin, W. S. T. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0740143.x · Cited by 115
Astrocytes and neuroinflammation in Alzheimer's disease
Phillips, E. C., Croft, C. L., Kurbatskaya, K., O’Neill, M. J., Hutton, M. L., Hanger, D. P., Garwood, C. J., & Noble, W. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140155 · Cited by 114
Interactive Effect of Obesity Indexes on Cognition
Jeong, S.-K., Nam, H.-S., Son, M.-H., Son, E.-J., & Cho, K.-H. (2005) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000082659 · Cited by 113
Jesse, S., Steinacker, P., Cepek, L., Arnim, C. V., Tumani, H., Lehnert, S., Kretzschmar, H. A., Baier, M., & Otto, M. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-1075 · Cited by 113
Effect of natural exogenous antioxidants on aging and on neurodegenerative diseases
Guerra‐Araiza, C., Álvarez-Mejía, L., Sánchez‐Torres, S., Farfán‐García, E. D., Mondragón‐Lozano, R., Pinto‐Almazán, R., & Salgado‐Ceballos, H. (2013) · Free Radical Research · doi:10.3109/10715762.2013.795649 · Cited by 125
Macrophages in Alzheimer’s disease: the blood-borne identity
Gate, D., Rezai-Zadeh, K., Jodry, D., Rentsendorj, A., & Town, T. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0422-7 · Cited by 107
“IL-6 has been purported to have a pathogenic role in AD because it is upregulated in the plasma, cerebrospinal fluid, and brain parenchyma of AD patients and is expressed at Ab plaques (Licastro et al. 2000; Huell et al. 1995).”
Anti-Inflammatory Impact of Minocycline in a Mouse Model of Tauopathy
Garwood, C. J., Cooper, J. D., Hanger, D. P., & Noble, W. (2010) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2010.00136 · Cited by 106
“A number of cytokines were found to be significantly decreased in response to minocycline treatment, including GM-CSF, M-CSF, I-309, eotaxin, MCP-1, MCP-5, IL-6, and TREM-1.”
BackgroundInfluentialMekhora, C., Lamport, D. J., & Spencer, J. P. E. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105900 · Cited by 117
“…that elevated inflammatory molecules in the postmortem brain tissue, plasma, or CSF have been associated with poor cognitive outcomes in AD (Janelidze et al., 2018; Huell et al., 1995; Cacabelos et al., 1994; Taipa et al., 2019; Galimberti et al., 2006; Hesse et al., 2016; Schmitz et al., 2015).”
Astrocyte changes in aging cerebral cortex and hippocampus: A quantitative immunohistochemical study
Amenta, F., Bronzetti, E., Sabbatini, M., & Vega, J. A. (1998) · Microscopy Research and Technique · doi:10.1002/(sici)1097-0029(19981001)43:1<29::aid-jemt5>3.0.co;2-h · Cited by 104
Fiebich, B. L., Mueksch, B., Boehringer, M., & Hüll, M. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0752020.x · Cited by 100
Eikelenboom, P., Rozemüller, A. J. M., & Muiswinkel, F. L. V. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6920 · Cited by 105
Interleukins, Inflammation, and Mechanisms of Alzheimer's Disease
Weisman, D., Hakimian, E., & Ho, G. J. (2006) · Vitamins & Hormones · doi:10.1016/s0083-6729(06)74020-1 · Cited by 95
Patients with Alzheimer's disease display a pro-inflammatory phenotype
Remarque, E. J., Bollen, E. L. E. M., Weverling‐Rijnsburger, A. W. E., Laterveer, J. C., Blauw, G. J., & Westendorp, R. G. J. (2001) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00176-5 · Cited by 95
Interleukin 6 and cognitive dysfunction
Trapero, I., & Cauli, O. (2014) · Metabolic Brain Disease · doi:10.1007/s11011-014-9551-2 · Cited by 107
“Huell et al. (1995) investigated the appearance of IL-6 immunoreactivity in AD plaques according to the stage of plaque formation and showed that IL-6 appeared to be linked to early plaque-formation stages, suggesting that it might be a factor related to the early histopathological changes…”
BackgroundHampel, H. J., Teipel, S. J., Padberg, F., Haslinger, A., Riemenschneider, M., Schwarz, M., Kötter, H. U., Scheloske, M., Buch, K., Stübner, S., et al. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01146-4 · Cited by 96
Hewett, S. J., Bell, S. C., & Hewett, J. A. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.04.011 · Cited by 100
“associated with the β-amyloid plaques in brains from AD patients (Eikelenboom & Stam, 1982; Abraham & Potter, 1989; Itagaki et al., 1989; McGeer et al., 1989; Tooyama et al., 1990; Griffin et al., 1995; Huell et al., 1995; Mackenzie et al., 1995; Mrak et al., 1995; Pike et al., 1995; Yasojima et al., 1999b).”
BackgroundFranceschi, C., Valensin, S., Lescai, F., Olivieri, F., Licastro, F., Grimaldi, L. M. E., Monti, D., BENEDICTIS, G. D., & Bonafè, M. (2001) · Aging Clinical and Experimental Research · doi:10.1007/bf03351475 · Cited by 98
Szczepanik, A. M., Rampe, D., & Ringheim, G. E. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.t01-1-00240.x · Cited by 87
Raber, J., O’Shea, R. D., Bloom, F. E., & Campbell, I. L. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-24-09473.1997 · Cited by 87
Inflammatory markers in Alzheimer's disease and multi-infarct dementia
Luigi, A. D., Fragiacomo, C., Lucca, U., Quadri, P., Tettamanti, M., & Simoni, M. G. D. (2001) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(01)00313-x · Cited by 86
Interleukin-6-associated inflammatory processes in Alzheimer's disease: new therapeutic options
Hüll, M., Fiebich, B. L., Lieb, K., Strauss, S., Berger, M., Volk, B., & Bauer, J. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00107-8 · Cited by 82
Self-citationEvert, B. O., Vogt, I. R., Vieira-Saecker, A. M. M., Ozimek, L., de Vos, R. A. I., Brunt, E. R. P., Klockgether, T., & Wüllner, U. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.10.1006 · Cited by 112
“In Alzheimer disease, IL6 has been detected in diffuse plaques, indicating local activation of inflammatory mechanisms (33, 34).”
BackgroundBlom, M. A. A., van Twillert, M. G. H., de Vries, S. C., Engels, F., Finch, C. E., Veerhuis, R., & Eikelenboom, P. (1997) · Brain Research · doi:10.1016/s0006-8993(97)01204-3 · Cited by 83
Neuroinflammation and Alzheimer Disease: Clinical and Therapeutic Implications
Eikelenboom, P., Rozemuller, A. J. M., Hoozemans, J. J. M., Veerhuis, R., & van Gool, W. A. (2000) · Alzheimer Disease and Associated Disorders · doi:10.1097/00002093-200000001-00009 · Cited by 78
Cell senescence in neuropathology: A focus on neurodegeneration and tumours
Carreno, G., Guiho, R., & Martinez‐Barbera, J. P. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12689 · Cited by 74
Neuroinflammatory Signaling in the Pathogenesis of Alzheimer’s Disease
Uddin, M. S., Kabir, M. T., Jalouli, M., Rahman, M. A., Jeandet, P., Behl, T., Alexiou, A. T., Albadrani, G. M., Abdel‐Daim, M. M., Perveen, A., et al. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210826130210 · Cited by 81
“Numerous studies have explored the molecular and cellular mechanisms underlying the relationship of IL-6 with AD involving Aβ and tau [97].”
BackgroundMärz, P., Heese, K., Höck, C., Golombowski, S., Müller-Spahn, F., Rose‐John, S., & Otten, U. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00886-0 · Cited by 79
Hoozemans, J. J. M., Veerhuis, R., Janssen, I., Rozemüller, A. J. M., & Eikelenboom, P. (2001) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00226-6 · Cited by 76
Nitric oxide in the cerebral cortex of amyloid-precursor protein (SW) Tg2576 transgenic mice
Rodrigo, J., Fernández‐Vizarra, P., Castro‐Blanco, S., Bentura, M. L., Nieto, M., Gómez‐Isla, T., Martínez‐Murillo, R., Martínez, A., Serrano, J., & Fernández, A. P. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2004.06.030 · Cited by 77
DOCAGNE, F., GABRIEL, C., LEBEURRIER, N., LESNÉ, S., HOMMET, Y., PLAWINSKI, L., MacKENZIE, E. T., & VIVIEN, D. (2004) · Biochemical Journal · doi:10.1042/bj20040682 · Cited by 69
Engelborghs, S., Brabander, M. D., Crée, J. D., D’Hooge, R., Geerts, H., Verhaegen, H., & Deyn, P. P. D. (1999) · Neurochemistry International · doi:10.1016/s0197-0186(99)00031-5 · Cited by 76
Interaction of atherosclerosis and inflammation in elderly subjects with poor cognitive function
van Exel, E., de Craen, A. J. M., Remarque, E. J., Gussekloo, J., Houx, P., Bootsma–van der Wiel, A., Frölich, M., Macfarlane, P. W., Blauw, G. J., & Westendorp, R. G. J. (2003) · Neurology · doi:10.1212/01.wnl.0000098877.07653.7c · Cited by 69
“History of arterial surgery 0 (0) 37 (11)”
BackgroundThe role of inflammatory processes in Alzheimer’s disease
Broussard, G. J., Mytar, J. O., Li, R., & Klapstein, G. J. (2012) · Inflammopharmacology · doi:10.1007/s10787-012-0130-z · Cited by 74
Hampel, H. J., Haslinger, A., Scheloske, M., Padberg, F., Fischer, P., Unger, J., Teipel, S. J., Neumann, M., Rosenberg, C., Oshida, R., et al. (2004) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-004-0558-2 · Cited by 73
“The brain region specific expression of IL-6 protein in AD patients has been investigated previously (Bauer et al. 1991; Hüll et al. 1995; Strauss et al. 1992), demonstrating IL-6 positive staining in plaques of AD patients in contrast to age-matched control samples (Bauer et al. 1991; Strauss et…”
BackgroundResultRingheim, G. E., & Conant, K. E. (2003) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2003.10.013 · Cited by 73
Decaffeinated coffee prevents scopolamine-induced memory impairment in rats
Jang, Y. J., Kim, J., Shim, J., Kim, C., Jang, J.-H., Lee, K. W., & Lee, H. J. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.02.003 · Cited by 72
Cytokines in Alzheimer's disease and multiple sclerosis
Patterson, P. H. (1995) · Current Opinion in Neurobiology · doi:10.1016/0959-4388(95)80070-0 · Cited by 71
Expression of CAP37, a Novel Inflammatory Mediator, in Alzheimer's Disease
Pereira, H. (1996) · Neurobiology of Aging · doi:10.1016/s0197-4580(96)00118-2 · Cited by 62
Expression of CAP37, a Novel Inflammatory Mediator, in Alzheimer's Disease
Pereira, H. A., Kumar, P., & Grammas, P. (1996) · Neurobiology of Aging · doi:10.1016/0197-4580(96)00118-2 · Cited by 62
Increased Pro-Inflammatory Response by Dendritic Cells from Patients with Alzheimer's Disease
Ciaramella, A., Bizzoni, F., Salani, F., Vanni, D., Spalletta, G., Sanarico, N., Vendetti, S., Caltagirone, C., & Bossù, P. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1257 · Cited by 62
“In fact, it was described that IL-6 is overexpressed in Aβ plaques [34] and, in the periphery, plasma IL-6 is significantly higher in AD patients than controls [35].”
Lieb, K., Schaller, H., Bauer, J., Berger, T., Schulze‐Osthoff, K., & Fiebich, B. L. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70041577.x · Cited by 60
Self-citationStübner, S., Schön, T., Padberg, F., Teipel, S. J., Schwarz, M. J., Haslinger, A., Buch, K., Dukoff, R., Lasser, R., Müller, N., et al. (1999) · Neuroscience Letters · doi:10.1016/s0304-3940(98)00916-1 · Cited by 59
Chong, Y.-H. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00936-3 · Cited by 64
Licastro, F., Chiappelli, M., Ruscica, M., Carnelli, V., & Corsi, M. M. (2005) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200501800117 · Cited by 59
Pharmacogenomics of neurodegenerative diseases
Maimone, D., Dominici, R., & Grimaldi, L. M. E. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00939-0 · Cited by 58
Zou, J., Cai, P., Xiong, C., & Ruan, J. (2016) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-016-1536-4 · Cited by 61
Cheng, S., Hou, J., Zhang, C., Xu, C., Wang, L., Zou, X., Yu, H., Shi, Y., Yin, Z., & Chen, G. (2015) · Scientific Reports · doi:10.1038/srep10535 · Cited by 57
Liu, M., Pan, J., Li, X., Zhang, X., Tian, F., Li, M., Wu, X., Zhang, L., & Qin, C. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03277-3 · Cited by 65
“Multiple studies have shown that IL-6 expression levels are significantly elevated in both the brain parenchyma [8, 9] and peripheral blood of AD patients [10–12], as well as in the brain parenchyma of AD animal models [13–15].”
BackgroundAltered apolipoprotein E secretion in cytokine treated human astrocyte cultures
Baskin, F., Smith, G. M., Fosmire, J. A., & Rosenberg, R. N. (1997) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(96)05335-x · Cited by 61
Advancing electrochemical biosensors for interleukin-6 detection
McCrae, L. E., Ting, W., & Howlader, M. M. R. (2022) · Biosensors and Bioelectronics X · doi:10.1016/j.biosx.2022.100288 · Cited by 61
Gambi, F., Reale, M., Iarlori, C., Salone, A., Toma, L., Paladini, C., De Luca, G., Feliciani, C., Salvatore, M., Salerno, R. M., et al. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000125683.74595.2f · Cited by 53
Alzheimer's disease and inflammatory biomarkers positively correlate in plasma in the UK‐ADRC cohort
Foley, K. E., Winder, Z., Sudduth, T. L., Martin, B. J., Nelson, P. T., Jicha, G. A., Harp, J. P., Weekman, E. M., & Wilcock, D. M. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13485 · Cited by 56
Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease
Hampel, H. J., Sunderland, T., Kötter, H. U., Schneider, C., Teipel, S. J., Padberg, F., Dukoff, R. A., Levy, J., & Möller, H. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01355-3 · Cited by 57
Molecular and cellular mediators of Alzheimer's disease inflammation
Strohmeyer, R., & Rogers, J. (2001) · Journal of Alzheimer's Disease · doi:10.3233/jad-2001-3118 · Cited by 51
Anti-inflammatory drugs: a hope for Alzheimer’s disease?
Hüll, M., Lieb, K., & Fiebich, B. L. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.4.671 · Cited by 60
McGeer, E. G., & McGeer, P. L. (1997) · CNS Drugs · doi:10.2165/00023210-199707030-00005 · Cited by 53
Härtig, W., Bauer, A., Brauer, K., Grosche, J., Hortobágyi, T., Penke, B., Schliebs, R., & Harkany, T. (2002) · Reviews in the Neurosciences · doi:10.1515/revneuro.2002.13.2.95 · Cited by 55
AlMatar, M., Islam, M. R., Albarri, O., Var, İ., & Köksal, F. (2017) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557517666170419114722 · Cited by 51
Rösler, N., Wichart, I., & Jellinger, K. A. (2001) · Journal of Neural Transmission · doi:10.1007/s007020170091 · Cited by 51
Metadata
- Authors
- Huell, M., Strauss, S., Volk, B., Berger, M., & Bauer, J.
- Affiliations
- University of Freiburg (DE)
- ORCID
- Strauss, Sylvia
- Venue
- Acta Neuropathologica
- Published
- 1995
- Volume
- 89
- Issue
- 6
- Pages
- 544-551
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W2001259634
- Cited by
- 214
- References
- 53
- Citations by year
- 2026: 3 · 2025: 6 · 2024: 8 · 2023: 9 · 2022: 8 · 2021: 7 · 2020: 6 · 2019: 3 · 2018: 3 · 2017: 2 · 2016: 4 · 2015: 5 · 2014: 8 · 2013: 2 · 2012: 4
- FWCI
- 8.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Acta Neuropathologica (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bundesministerium für Forschung und Technologie
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- interleukin-6, Alzheimer's disease, amyloid plaques, plaque type, diffuse plaques, amyloid precursor protein, cerebral cortex, dementia, neuroinflammation
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Brain Chemistry, Humans, Immunohistochemistry, Middle Aged, Interleukin-6, Silver Staining
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.